MIDAS Strategy: Minimizing Implantat Depth According to Membranous Septum

Permanent pacemaker implantation following transcatheter aortic valve replacement (TAVR) continues to be one of the most frequent complications. Even though its real impact on prognosis continues to be controversial, its impact on healthcare cost is out of the question, in addition to being uncomfortable for patients. 

¿Fin de la discusión sobre el impacto del marcapaso post TAVI?

This study, soon to be published in J Am Coll Cardiol Intv, sought a way to minimize the risk of pacemaker implantation post TAVR with contemporary repositionable self-expanding transcatheter aortic valve replacement (TAVR).

It included 248 consecutive severe aortic stenosis patients undergoing self-expanding TAVR under conscious sedation with standard approach. Researchers looked at multiple factors that might contribute to definite pacemaker implantation rate and created an anatomically guided minimizing depth according to membranous septum (MIDAS). The idea behind this technique is to minimize implant depth relative to non-coronary sinus/ membranous septum distance. 


Read also: The Era of Provisional Stenting for Bifurcations Comes to an End.


Pacemaker implantation predictors post TAVR were prior right bundle branch block, membranous septum length, larger devices (Evolut 34 XL) and deeper implantation relative to non-coronary cusp /membranous septum distance.

At multivariable analyzis, the only independent predictors were deeper implantation than the distance to membranous sinus (OR: 8.04 CI 95%: 2.58 to 25.04]; p<0.001) and Evolut 34 XL prosthesis (OR: 4.96 CI 95%: 1.68 to 14.63]; p=0.004).

The MIDAS technique was done prospectively in 100 consecutive patients after this analyzis. Operators’ goal was pre-release depth in relation to the noncoronary cusp of less than the length of the membranous septum.

With this technique, researchers succeeded in reducing pacemaker implantation rate from 9.7% to 3% (p=0.035) and left bundle branch block from 25.8% to 9% (p<0.001).

Conclusion

Using the MIDAS technique, we can find the right implantation depth specific to each patient, which predicts and reduces definite pacemaker implantation rate post self-expandable contemporary valve implantation. 

Original Title: Minimizing Permanent Pacemaker Following Repositionable Self-Expanding Transcatheter Aortic Valve Replacement.

Reference: Hasan Jilaihawi et al. J Am Coll Cardiol Intv 2019, online before print.



Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | TRISCEND II

This randomized study included 400 patients; 267 were treated with EVOQUE valve and 133 with optimal medical treatment (OMT). After one-year follow-up, there were no...

TCT 2024 – ACCESS-TAVI: Comparing Percutaneous Access Closure Strategies After TAVI

Vascular access complications following transcatheter aortic valve implantation (TAVI) remain common. However, few studies compare vascular access closure methods.  Based on the CHOICE-CLOSURE and MASH...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

TCT 2024 | Asymptomatic Severe Aortic Stenosis: What Should Be our Approach?

Approximately 3% of the population over 65 years old has aortic stenosis. Current guidelines recommend valve replacement for patients with symptoms or an ejection...

TCT 2024 | FAVOR III EUROPA

The study FAVOR III EUROPA, a randomized trial, included 2,000 patients with chronic coronary syndrome, or stabilized acute coronary syndrome, and intermediate lesions. 1,008...